AstraZeneca PLC
AstraZeneca PLC (AZN) Stock Competitors & Peer Comparison
See (AZN) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AZN | $74.48 | -0.15% | 462B | 28.11 | $2.65 | +2.07% |
| LLY | $765.95 | -0.40% | 726B | 62.43 | $12.27 | +0.73% |
| JNJ | $170.74 | -0.18% | 411.2B | 18.28 | $9.34 | +2.95% |
| ABBV | $198.55 | +0.69% | 350.6B | 94.98 | $2.09 | +3.26% |
| NVS | $117.73 | -0.08% | 228.7B | 17.16 | $6.86 | +3.39% |
| NVO | $47.22 | -3.26% | 208.8B | 12.93 | $3.65 | +3.40% |
| MRK | $80.79 | +1.16% | 202.9B | 12.45 | $6.49 | +3.96% |
| AMGN | $300.08 | -0.62% | 161.4B | 27.38 | $10.96 | +3.10% |
| PFE | $24.75 | +5.16% | 140.6B | 17.92 | $1.38 | +6.89% |
| GILD | $112.46 | -1.79% | 139.9B | 14.53 | $7.74 | +2.76% |
Stock Comparison
AZN vs LLY Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, LLY has a market cap of 726B. Regarding current trading prices, AZN is priced at $74.48, while LLY trades at $765.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas LLY's P/E ratio is 62.43. In terms of profitability, AZN's ROE is +0.20%, compared to LLY's ROE of +0.77%. Regarding short-term risk, AZN is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check LLY's competition here
AZN vs JNJ Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, JNJ has a market cap of 411.2B. Regarding current trading prices, AZN is priced at $74.48, while JNJ trades at $170.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas JNJ's P/E ratio is 18.28. In terms of profitability, AZN's ROE is +0.20%, compared to JNJ's ROE of +0.30%. Regarding short-term risk, AZN is less volatile compared to JNJ. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check JNJ's competition here
AZN vs ABBV Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, ABBV has a market cap of 350.6B. Regarding current trading prices, AZN is priced at $74.48, while ABBV trades at $198.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas ABBV's P/E ratio is 94.98. In terms of profitability, AZN's ROE is +0.20%, compared to ABBV's ROE of +0.86%. Regarding short-term risk, AZN is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check ABBV's competition here
AZN vs NVS Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, NVS has a market cap of 228.7B. Regarding current trading prices, AZN is priced at $74.48, while NVS trades at $117.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas NVS's P/E ratio is 17.16. In terms of profitability, AZN's ROE is +0.20%, compared to NVS's ROE of +0.23%. Regarding short-term risk, AZN is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for AZN.Check NVS's competition here
AZN vs NVO Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, NVO has a market cap of 208.8B. Regarding current trading prices, AZN is priced at $74.48, while NVO trades at $47.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas NVO's P/E ratio is 12.93. In terms of profitability, AZN's ROE is +0.20%, compared to NVO's ROE of +0.81%. Regarding short-term risk, AZN is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check NVO's competition here
AZN vs MRK Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, MRK has a market cap of 202.9B. Regarding current trading prices, AZN is priced at $74.48, while MRK trades at $80.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas MRK's P/E ratio is 12.45. In terms of profitability, AZN's ROE is +0.20%, compared to MRK's ROE of +0.38%. Regarding short-term risk, AZN is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check MRK's competition here
AZN vs AMGN Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, AMGN has a market cap of 161.4B. Regarding current trading prices, AZN is priced at $74.48, while AMGN trades at $300.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas AMGN's P/E ratio is 27.38. In terms of profitability, AZN's ROE is +0.20%, compared to AMGN's ROE of +0.93%. Regarding short-term risk, AZN is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check AMGN's competition here
AZN vs PFE Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, PFE has a market cap of 140.6B. Regarding current trading prices, AZN is priced at $74.48, while PFE trades at $24.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas PFE's P/E ratio is 17.92. In terms of profitability, AZN's ROE is +0.20%, compared to PFE's ROE of +0.12%. Regarding short-term risk, AZN is less volatile compared to PFE. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check PFE's competition here
AZN vs GILD Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, GILD has a market cap of 139.9B. Regarding current trading prices, AZN is priced at $74.48, while GILD trades at $112.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas GILD's P/E ratio is 14.53. In terms of profitability, AZN's ROE is +0.20%, compared to GILD's ROE of +0.32%. Regarding short-term risk, AZN is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check GILD's competition here
AZN vs SNY Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, SNY has a market cap of 116.7B. Regarding current trading prices, AZN is priced at $74.48, while SNY trades at $47.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas SNY's P/E ratio is 16.05. In terms of profitability, AZN's ROE is +0.20%, compared to SNY's ROE of +0.12%. Regarding short-term risk, AZN is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for AZN.Check SNY's competition here
AZN vs BMY Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, BMY has a market cap of 93.3B. Regarding current trading prices, AZN is priced at $74.48, while BMY trades at $45.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas BMY's P/E ratio is 18.41. In terms of profitability, AZN's ROE is +0.20%, compared to BMY's ROE of +0.30%. Regarding short-term risk, AZN is less volatile compared to BMY. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check BMY's competition here
AZN vs CELG-RI Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, CELG-RI has a market cap of 87.5B. Regarding current trading prices, AZN is priced at $74.48, while CELG-RI trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, AZN's ROE is +0.20%, compared to CELG-RI's ROE of +0.30%. Regarding short-term risk, AZN is more volatile compared to CELG-RI. This indicates potentially higher risk in terms of short-term price fluctuations for AZN.Check CELG-RI's competition here
AZN vs GSK Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, GSK has a market cap of 75.3B. Regarding current trading prices, AZN is priced at $74.48, while GSK trades at $37.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas GSK's P/E ratio is 17.05. In terms of profitability, AZN's ROE is +0.20%, compared to GSK's ROE of +0.24%. Regarding short-term risk, AZN is less volatile compared to GSK. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check GSK's competition here
AZN vs HZNP Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, AZN is priced at $74.48, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas HZNP's P/E ratio is 61.86. In terms of profitability, AZN's ROE is +0.20%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, AZN is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for AZN.Check HZNP's competition here
AZN vs BIIB Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, BIIB has a market cap of 19.5B. Regarding current trading prices, AZN is priced at $74.48, while BIIB trades at $132.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas BIIB's P/E ratio is 12.72. In terms of profitability, AZN's ROE is +0.20%, compared to BIIB's ROE of +0.09%. Regarding short-term risk, AZN is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check BIIB's competition here
AZN vs GRFS Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, GRFS has a market cap of 8.9B. Regarding current trading prices, AZN is priced at $74.48, while GRFS trades at $10.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas GRFS's P/E ratio is 21.26. In terms of profitability, AZN's ROE is +0.20%, compared to GRFS's ROE of +0.05%. Regarding short-term risk, AZN is less volatile compared to GRFS. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check GRFS's competition here
AZN vs OGN Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, OGN has a market cap of 2.2B. Regarding current trading prices, AZN is priced at $74.48, while OGN trades at $8.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas OGN's P/E ratio is 2.91. In terms of profitability, AZN's ROE is +0.20%, compared to OGN's ROE of +1.82%. Regarding short-term risk, AZN is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check OGN's competition here
AZN vs CTOR Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, CTOR has a market cap of 141.9M. Regarding current trading prices, AZN is priced at $74.48, while CTOR trades at $1.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas CTOR's P/E ratio is -4.76. In terms of profitability, AZN's ROE is +0.20%, compared to CTOR's ROE of -0.34%. Regarding short-term risk, AZN is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check CTOR's competition here
AZN vs SCLX Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, SCLX has a market cap of 97.3M. Regarding current trading prices, AZN is priced at $74.48, while SCLX trades at $13.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas SCLX's P/E ratio is -0.82. In terms of profitability, AZN's ROE is +0.20%, compared to SCLX's ROE of +0.36%. Regarding short-term risk, AZN is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check SCLX's competition here
AZN vs SCLXW Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, SCLXW has a market cap of 78M. Regarding current trading prices, AZN is priced at $74.48, while SCLXW trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas SCLXW's P/E ratio is N/A. In terms of profitability, AZN's ROE is +0.20%, compared to SCLXW's ROE of +0.36%. Regarding short-term risk, AZN is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check SCLXW's competition here
AZN vs MIRA Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, MIRA has a market cap of 26.6M. Regarding current trading prices, AZN is priced at $74.48, while MIRA trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas MIRA's P/E ratio is -3.19. In terms of profitability, AZN's ROE is +0.20%, compared to MIRA's ROE of -3.41%. Regarding short-term risk, AZN is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check MIRA's competition here
AZN vs SRXH Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, SRXH has a market cap of 13.9M. Regarding current trading prices, AZN is priced at $74.48, while SRXH trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas SRXH's P/E ratio is N/A. In terms of profitability, AZN's ROE is +0.20%, compared to SRXH's ROE of -0.50%. Regarding short-term risk, AZN is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check SRXH's competition here
AZN vs CRXT Comparison August 2025
AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AZN stands at 462B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, AZN is priced at $74.48, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AZN currently has a P/E ratio of 28.11, whereas CRXT's P/E ratio is -0.02. In terms of profitability, AZN's ROE is +0.20%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, AZN is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check CRXT's competition here